Apolipoproteins E and C-III in apo B- and non-apo B-containing lipoproteins in middle-aged women from the Stanislas cohort: effect of oral contraceptive use and common apolipoprotein E polymorphism.
Oral contraceptive (OC) use and common apo E polymorphism are well known to modify serum lipid and lipoprotein concentrations. The combined effect of OC use and apo E genotype on the concentration of apo E or apo C-III in apo B- (apo E-LpB or apo C-III-LpB) or in non-apo B-containing lipoparticles (apo E-Lp-non-B or apo C-III-Lp-non-B) are unknown. Our study comprised 613 women, aged 30-45 years, genotyped for common apo E polymorphism and who differed in their combined low-dose OC consumption. The concentrations of apo C-III, apo C-III-LpB and apo C-III-Lp-non-B were significantly higher in OC users than in non-users by 13, 23 and 8% respectively, without significant interaction with the apo E genotype. The concentrations of apo E and apo E-Lp-non-B were significantly lower (differences being -14% and -31% respectively) in OC users than in controls whereas the apo E-LpB concentration was significantly higher (+19%), resulting in a redistribution of apo E from Lp-non-B towards LpB. Total apo E and apo E-Lp-non-B concentrations were higher in subjects carrying the epsilon2 allele and lower in those with the epsilon4 allele when compared to epsilon3/epsilon3 subjects (P < 0.001). The opposite held for the apo E- LpB concentration (P < 0.05). The main finding is the significant interaction between apo E genotype and OC use (P < 0.01) on apo E-Lp-non-B concentration, the epsilon4 carriers showing the smallest differences between OC users and non-users in comparison with the epsilon2 or epsilon3/epsilon3 carriers. These results suggest that the common apo E polymorphism can modulate the OC use effect.
Centre de Médecine Préventive, Université Henri Poincaré (Nancy I), E.A: Interaction gène environnement, Vandoeuvre-lès-Nancy, France.
M
M
Starck
F
F
Schiele
B
B
Herbeth
M
M
Vincent-Viry
B
B
Beaud
G
G
Siest
S
S
Visvikis
D000328:Adult; D053305:Apolipoprotein C-III; D053327:Apolipoprotein E4; D001055:Apolipoproteins B / Q000097:blood*; D001056:Apolipoproteins C / Q000097:blood*; D001057:Apolipoproteins E / Q000097:blood* / Q000235:genetics; D015992:Body Mass Index; D002318:Cardiovascular Diseases / Q000453:epidemiology; D002784:Cholesterol / Q000097:blood; D015331:Cohort Studies; D003278:Contraceptives, Oral, Hormonal / Q000009:adverse effects / Q000494:pharmacology*; D005260:Female; D005602:France / Q000453:epidemiology; D005838:Genotype; D006801:Humans; D006949:Hyperlipidemias / Q000453:epidemiology; D008074:Lipoproteins / Q000097:blood*; D008875:Middle Aged; D011110:Polymorphism, Genetic; D020033:Protein Isoforms / Q000097:blood* / Q000235:genetics; D012307:Risk Factors; D014280:Triglycerides / Q000097:blood
D053305:Apolipoprotein C-III; D053327:Apolipoprotein E4; D001055:Apolipoproteins B; D001056:Apolipoproteins C; D001057:Apolipoproteins E; D003278:Contraceptives, Oral, Hormonal; D008074:Lipoproteins; D020033:Protein Isoforms; D014280:Triglycerides; D002784:Cholesterol